Announcements Trials

Browse Landscape

Status

Sponsor Class

Study Type

Observational 1

Sponsor

Cancer Type

Breast 24 Gastrointestinal 18 Thoracic 17 Genitourinary 15 CNS 11 Tumor-Agnostic 8 Dermatologic 8 Gynecologic 7 Lymphoid 6 Head & Neck 6 Other hematologic neoplasm 5 Myeloid 5 Other solid neoplasm 4 Sarcoma 3 Endocrine 3 Classical hematology 2 Plasma cell 1 NET 1

Conditions

Neuroendocrine Tumors 1

Interventions

lutetium Lu 177 dotatate 13 Specimen Handling 8 Magnetic Resonance Spectroscopy 8 Everolimus 8 cabozantinib 6 pembrolizumab 5 Nivolumab 4 olaparib 3 lenvatinib 3 X-Rays 3 Lutetium-177 3 177Lu-octreotide, DOTA(0)-Tyr(3)- 3 lanreotide 2 gallium Ga 68 dotatate 2 avelumab 2 amino-acid, glucose, and electrolyte solution 2 Sunitinib 2 Radiotherapy 2 Phantoms, Imaging 2 Octreotide 2 Ipilimumab 2 Fluorodeoxyglucose F18 2 Etoposide 2 Cyclophosphamide 2 Cisplatin 2 3-aminopyridine-2-carboxaldehyde thiosemicarbazone 2 telotristat ethyl 1 surufatinib 1 repotrectinib 1 peposertib 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Blood Specimen Collection × NET × 90 days × Clear all

NCT06430021 2026-05-22

PRO-NEM1

Centre Hospitalier Universitaire Dijon

Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon ⚡